Stryker (NYSE: SYK) + announced today that it completed the acquisition of Nico Corporation, a neurotechnology company.

Financial terms of the deal were not disclosed.

This marks the second acquisition completed this week by Stryker, following the closing of its Care.ai acquisition on Sept. 18.

Nico offers a systemic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. It develops the BrainPath and Myriad products as treatment options for ICH with improved functional outcomes compared to guideline-based medical management alone, the current standard of care.

Stryker says the acquisition further strengthens its commitment to neurotechnology through tumor and stroke care.

“The acquisition of Nico Corporation expands Stryker’s portfolio of solutions for tumor resection and the treatment of intracerebral hemorrhage, the deadliest form of stroke,” said Andy Pierce, group president, MedSurg and Neurotechnology, Stryker. “As a global leader in neurosurgical access and removal tools, this strategic addition enables us to deliver differentiated, minimally invasive approaches that will drive meaningful outcomes and improve the lives of patients worldwide.”

Stryker has been very active on the M&A front recently, in addition to the Care.ai and Nico deals. In the past few months alone, the company announced four different deals.

In July, the company completed its acquisition of Artelon, then closed its purchase of Molli Surgical just two weeks later. Then, in August, Stryker made a pain management move, agreeing to acquire Vertos Medical. Just last week, the company made another deal, announcing the acquisition of new Foot & Ankle portfolio products from 4WEB Medical.